Comparación de los anticoagulantes nuevos con la warfarina | 19 MAY 14

Anticoagulación en la fibrilación auricular

Debate sobre los antecedentes y la justificación de la anticoagulación prolongada; clasificación de riesgos; selección y manejo farmacológico de la warfarina y los anticoagulantes nuevos.
Autor/a: Dres. Benjamin A Steinberg, Jonathan P Piccini BMJ 2014;348:g2116
INDICE:  1.  | 2. Referencias
Referencias

01.↵Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-5.CrossRefMedlineWeb of Science
02.↵Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, Buring JE, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA2011;305:2080-7.CrossRefMedlineWeb of Science
03.↵Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation1998;98:946-52.Abstract/FREE Full Text
04.↵Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology1978;28:973-7.CrossRef
05.↵Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med1987;147:1561-4.CrossRefMedlineWeb of Science
06.↵Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke1996;27:1760-4.Abstract/FREE Full Text
07.↵Tu HT, Campbell BC, Christensen S, Collins M, De Silva DA, Butcher KS, et al. Pathophysiological determinants of worse stroke outcome in atrial fibrillation. Cerebrovasc Dis2010;30:389-95.CrossRefMedline
08.↵McGrath ER, Kapral MK, Fang J, Eikelboom JW, O’Conghaile A, Canavan M, et al. Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology2013;81:825-32.CrossRef
09.↵Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA2003;290:2685-92.CrossRefMedlineWeb of Science
10.↵Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med2007;146:857-67.CrossRefMedlineWeb of Science
11.↵Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke2012;43:1795-9.Abstract/FREE Full Text
12.↵Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation2014;129:837-47.Abstract/FREE Full Text
13.↵Lloyd-Jones DM. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation2004;110:1042-46.Abstract/FREE Full Text
14.↵Piccini JP, Hammill BG, Sinner MF, Jensen PN, Hernandez AF, Heckbert SR, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007. Circ Cardiovasc Qual Outcomes2012;5:85-93.Abstract/FREE Full Text
15.↵Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart2001;86:516-21.Abstract/FREE Full Text
16.↵Dewland TA, Olgin JE, Vittinghoff E, Marcus GM. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. Circulation2013;128:2470-7.Abstract/FREE Full Text
17.↵Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham study. JAMA1985;254:3449-53.CrossRefMedlineWeb of Science
18.↵Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke1991;22:983-8.Abstract/FREE Full Text
19.↵Anderson DC, Kappelle LJ, Eliasziw M, Babikian VL, Pearce LA, Barnett HJ. Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. Stroke2002;33:1963-7.Abstract/FREE Full Text
20.↵Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The stroke prevention in atrial fibrillation investigators committee on echocardiography. Ann Intern Med1998;128:639-47.CrossRefMedlineWeb of Science
21.↵Uno M, Tsuji H, Sawada S, Toyoda T, Nakagawa M. Fibrinopeptide A (FPA) levels in atrial fibrillation and the effects of heparin administration. Jpn Circ J1988;52:9-12.CrossRefMedline
22.↵Mitusch R, Siemens HJ, Garbe M, Wagner T, Sheikhzadeh A, Diederich KW. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost1996;75:219-23.MedlineWeb of Science
23.↵Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. JAMA2001;285:2864-70.CrossRefMedlineWeb of Science
24.↵Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ2011;342:d124. Abstract/FREE Full Text
25.↵Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest2010;137:263-72.CrossRefMedlineWeb of Science
26.↵Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest2010;138:1093-100.CrossRefMedlineWeb of Science
27.↵Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol2011;58:395-401.CrossRefMedlineWeb of Science
28.↵Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J2012;33:1500-10.Abstract/FREE Full Text
29.↵Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J2010;31:2369-429.FREE Full Text
30.↵Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost2011;106:528-38.CrossRefMedline
31.↵Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the national registry of atrial fibrillation (NRAF). Am Heart J2006;151:713-9.CrossRefMedlineWeb of Science
32.↵Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation2012;125:2298-307.Abstract/FREE Full Text
33.↵Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J2012;33:2719-47.FREE Full Text
34.↵Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet1994;343:687-91.CrossRefMedlineWeb of Science
35.↵Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators. Stroke 1990;21:538-45.Abstract/FREE Full Text
36.↵Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med1992;327:1406-12.CrossRefMedlineWeb of Science
37.↵Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet1989;1:175-9.MedlineWeb of Science
38.↵Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA1999;281:1830-5.CrossRefMedlineWeb of Science
39.↵Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet2006;367:1903-12.CrossRefMedlineWeb of Science
40.↵Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med2009;361:1139-51.CrossRefMedlineWeb of Science
41.↵Boehringer-Ingelheim. Dabigatran prescribing information. Secondary dabigatran prescribing information 2010. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf.
42.↵Boehringer-Ingelheim. Dabigatran prescribing information for stroke prevention in atrial fibrillation in the United Kingdom. 2013. www.pradaxa.co.uk/downloads/pi-spaf.pdf.
43.↵Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83.CrossRefMedlineWeb of Science
44.↵Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012;43:1511-7.Abstract/FREE Full Text
45.↵Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Peri-procedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY randomized trial. Circulation2012;126:343-8.Abstract/FREE Full Text
46.↵Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med2013;369:1206-14.CrossRefMedlineWeb of Science
47.↵Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation2013;128:237-43.Abstract/FREE Full Text
48.↵Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med2012;172:397-402.CrossRefMedlineWeb of Science
49.↵Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol2013;61:2264-73.CrossRefMedlineWeb of Science
50.↵Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med2013;368:1272-4.CrossRefMedlineWeb of Science
51.↵Sorensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open2013;3:2758.CrossRef
52.↵ROCKET AF Study Investigators. Rivaroxaban-Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J2010;159:340-47.CrossRefMedlineWeb of Science
53.↵Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med2011;365:883-91.CrossRefMedlineWeb of Science
54.↵Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J2011;32:2387-94.Abstract/FREE Full Text
55.↵Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation2008;118:2029-37.Abstract/FREE Full Text
56.↵Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res2009;124:37-41.CrossRefMedlineWeb of Science
57.↵Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost1993;69:236-9. MedlineWeb of Science
58.↵Food and Drug Administration. FDA draft briefing document for the cardiovascular and renal drugs advisory committee (CRDAC): rivaroxaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. 2011. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm270796.pdf.
59.↵Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol2013;61:651-8.CrossRefMedlineWeb of Science
60.↵Mahaffey KW, Hellkamp AS, Patel MR, Hannan KL, Schwabe K, Nessel CC, et al. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circ Cardiovasc Qual Outcomes 2013;6:470-8.Abstract/FREE Full Text
61.↵Lopes RD, Garcia DA, Wojdyla D, Dorian P, Alexander JH, Wallentin L, et al. Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE. Eur Heart J2013;34(suppl 1): doi:10.1093/eurheartj/eht307.P535.
62.↵Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study. Circ J2012;76:2104-11.CrossRefMedlineWeb of Science
63.↵Pharmaceuticals J. Rivaroxaban prescribing information. Secondary rivaroxaban prescribing information 2011. www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100.
64.↵Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med2011;364:806-17.CrossRefMedlineWeb of Science
65.↵Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med2011;365:981-92.CrossRefMedlineWeb of Science
66.↵Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D, et al. Outcomes of apixaban vs warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J2013;34:2464-71.Abstract/FREE Full Text
67.↵Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation2013;127:2166-76.Abstract/FREE Full Text
68.↵Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012;380:1749-58.CrossRefMedlineWeb of Science
69.↵Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med2013;369:2093-104.CrossRefMedlineWeb of Science
70.↵Hashimoto T, Suzuki K, Kihara Y, Iwatsubo T, Miyashita A, Heeringa M, et al. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica 2013;43:534-47.CrossRefMedlineWeb of Science
71.↵Connolly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J2013;34:1498-505.Abstract/FREE Full Text
72.↵Johansson S, Cullberg M, Eriksson UG, et al. Single-dose pharmacokinetics, pharmacodynamics and safety of AZD0837, a novel oral direct thrombin inhibitor, in young healthy male subjects. Int J Clin Pharmacol Ther2011;49:258-67.CrossRefMedline
73.↵Bartus K, Han FT, Bednarek J, Elg M, Duner K, Jensen E, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol2013;62:108-18.MedlineWeb of Science
74.↵Bartus K, Bednarek J, Myc J, Myc J, Kapelak B, Sadowski J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm2011;8:188-93.CrossRefMedlineWeb of Science
75.↵Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation2013;127:720-9.Abstract/FREE Full Text
76.↵Reddy VY, Holmes D, Doshi SK, , Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the continued access registry. Circulation2011;123:417-24.Abstract/FREE Full Text
77.↵Landmesser U, Holmes DR Jr. Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation. Eur Heart J2012;33:698-704.Abstract/FREE Full Text
78.↵Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: antithrombotic therapy and prevention of thrombosis (9th ed). American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(suppl 2):7S-47S.CrossRefMedlineWeb of Science
79.↵Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest2008;133(suppl 6):546S-92S.CrossRefMedlineWeb of Science
80.↵Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet2013; published 4 Dec.
81.↵Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace2013;15:625-5.Abstract/FREE Full Text
82.Squibb B-M. Apixaban prescribing information. Secondary apixaban prescribing information 2012. http://packageinserts.bms.com/pi/pi_eliquis.pdf.
83.Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov2011;10:61-75.CrossRefMedline
84.↵Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet2009;48:1-22.CrossRefMedlineWeb of Science
85.Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem2007;50:5339-56.CrossRefMedline
86.↵Lip GY, Larsen TB, Skjoth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012;60:738-46.CrossRefMedlineWeb of Science
87.↵Dogliotti A, Paolasso E, Giugliano RP. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients. Heart 2013; published online 5 Sep.
88.↵Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation2013;127:224-32.Abstract/FREE Full Text
89.↵Beasley BN, Unger EF, Temple R. Anticoagulant options—why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med2011;364:1788-90.CrossRefMedlineWeb of Science
90.↵Limone BL, Baker WL, Kluger J, Coleman CI. Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One2013;8:e62183.CrossRefMedline
91.↵Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation2011;124:1573-9.Abstract/FREE Full Text
92.↵Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med2008;168:63-9.CrossRefMedlineWeb of Science
93.↵Wysokinski WE, McBane RD, Daniels PR, Litin SC, Hodge DO, Dowling NF, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc2008;83:639-45.CrossRefMedlineWeb of Science
94.↵Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis (9th ed). American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141(suppl 2):e326S-50S.CrossRefMedlineWeb of Science
95.↵Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost2012;108:217-24.CrossRefMedline
96.↵Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from ROCKET AF. Circulation 2014; published online 19 Feb.
97.↵Bauer KA. Reversal of antithrombotic agents. Am J Hematol2012;87(suppl 1):S119-26.CrossRefMedline
98.↵Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013;19:446-51.CrossRefMedline
99.↵Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation2013;128:2325-32.Abstract/FREE Full Text
100.↵Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2011;123:e269-367.FREE Full Text
 

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024